For research use only. Not for therapeutic Use.
BGG463（Cat No.:I019839）is a selective inhibitor of the enzyme phosphatidylinositol 3-kinase (PI3K), specifically targeting the p110α isoform. This compound has garnered attention in cancer research due to its ability to disrupt the PI3K/Akt signaling pathway, which is often aberrantly activated in various malignancies. By inhibiting this pathway, BGG463 can induce apoptosis and inhibit cell proliferation in cancer cells. Preclinical studies have shown its potential effectiveness against several tumor types, making it a candidate for targeted cancer therapies. Ongoing research aims to elucidate its safety profile and therapeutic applications in clinical settings.
| Catalog Number | I019839 |
| CAS Number | 890129-26-7 |
| Molecular Formula | C₃₀H₂₉F₃N₆O₃ |
| Purity | ≥95% |
| Target | CDK |
| Storage | Store at -20°C |
| IUPAC Name | 6-(6-acetamidopyrimidin-4-yl)oxy-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide |
| InChI | InChI=1S/C30H29F3N6O3/c1-19(40)36-27-16-28(35-18-34-27)42-23-8-9-24-20(14-23)4-3-5-25(24)29(41)37-22-7-6-21(26(15-22)30(31,32)33)17-39-12-10-38(2)11-13-39/h3-9,14-16,18H,10-13,17H2,1-2H3,(H,37,41)(H,34,35,36,40) |
| InChIKey | MZZJNOOADWVFPD-UHFFFAOYSA-N |
| SMILES | CC(=O)NC1=CC(=NC=N1)OC2=CC3=C(C=C2)C(=CC=C3)C(=O)NC4=CC(=C(C=C4)CN5CCN(CC5)C)C(F)(F)F |
| Reference | [1]. Alexander LT, et al. Type II Inhibitors Targeting CDK2. ACS Chem Biol. 2015 Sep 18;10(9):2116-25.<br>[2]. Jones K, et al. Cancer Drug Discovery 2010: from molecules to medicine. Expert Rev Clin Pharmacol. 2010 Sep;3(5):613-5. |
